Therapeutic approaches to preventing cell death in Huntington disease

Progress in Neurobiology

Volumn 99, Issue 3, 2012, Pages 262-280

  Kaplan, Anna ^a   Stockwell, Brent R ^a  

^a Och Spine at New York Presbyterian Hospitals   (United States)

Author keywords

Cell death; Fragment based drug discovery; Huntington disease; Neurodegenerative diseases

Indexed keywords

AC 0523; ALPHA TOCOTRIENOL QUINONE; AV 101; CASPASE 3; CASPASE 6; CASPASE 8; CENTRAL NERVOUS SYSTEM AGENTS; CERE 120; CHLORPROMAZINE; CLONAZEPAM; CLOZAPINE; COQ 10; CX 929; ESCITALOPRAM; FLUOXETINE; GM 6; HALOPERIDOL; HD 02; HUNTINGTIN; INTERLEUKIN 1BETA CONVERTING ENZYME; LAMOTRIGINE; LNK 754; LSD 1; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; NORTRIPTYLINE; OLANZAPINE; PN 401; PRIDOPIDINE; PRO 289; PROTEIN DISULFIDE ISOMERASE; PROTEIN FARNESYLTRANSFERASE INHIBITOR; RP 103; SERTRALINE; TETRABENAZINE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VALPROATE SEMISODIUM; VALPROIC ACID; VAR 10300;

AUTOPHAGY; CELL DEATH; CHOREA; DEGENERATIVE DISEASE; DRUG DESIGN; DRUG DEVELOPMENT; FRAGMENT BASED DRUG DISCOVERY; HIGH THROUGHPUT SCREENING; HUMAN; HUNTINGTON CHOREA; MITOCHONDRION; NONHUMAN; OCCUPATIONAL THERAPY; PHOSPHORUS NUCLEAR MAGNETIC RESONANCE; PHYSIOTHERAPY; PRIORITY JOURNAL; PROTEIN STRUCTURE; REVIEW; WILD TYPE;

ANIMALS; CELL DEATH; DISEASE MODELS, ANIMAL; DRUG DESIGN; DRUG DISCOVERY; HUMANS; HUNTINGTON DISEASE; SMALL MOLECULE LIBRARIES;

EID: 84869883424     PISSN: 03010082     EISSN: 18735118     Source Type: Journal    
DOI: 10.1016/j.pneurobio.2012.08.004     Document Type: Review

References (276)

1. Accera, Inc., 2012. Product Pipeline. Retrieved February 5, 2012 from http://www.accerapharma.com/products.html.
2. Adam O.R., Jankovic J. Symptomatic treatment of Huntington disease. Neurotherapeutics 2008, 5:181-197.
3. Adlard P.A., Cherny R.A., Finkelstein D.I., Gautier E., Robb E., Cortes M., Volitakis I., Liu X., Smith J.P., Perez K., Laughton K., Li Q.X., Charman S.A., Nicolazzo J.A., Wilkins S., Deleva K., Lynch T., Kok G., Ritchie C.W., Tanzi R.E., Cappai R., Masters C.L., Barnham K.J., Bush A.I. Rapid restoration of cognition in Alzheimer's transgenic mice with 8-hydroxy quinoline analogs is associated with decreased interstitial Abeta. Neuron 2008, 59:43-55.
4. Alberch J., Perez-Navarro E., Canals J.M. Neuroprotection by neurotrophins and GDNF family members in the excitotoxic model of Huntington's disease. Brain Research Bulletin 2002, 57:817-822.
5. Aiken C.T., Tobin A.J., Schweitzer E.S. A cell-based screen for drugs to treat Huntington's disease. Neurobiology of Disease 2004, 16:546-555.
6. Alex A.A., Flocco M.M. Fragment-based drug discovery: what has it achieved so far?. Current Topics in Medicinal Chemistry 2007, 7:1544-1567.
7. Allen D.A., Pham P., Choong I.C., Fahr B., Burdett M.T., Lew W., DeLano W.L., Gordon E.M., Lam J.W., O'Brien T., Lee D. Identification of potent and novel small-molecule inhibitors of caspase-3. Bioorganic & Medicinal Chemistry Letters 2003, 13:3651-3655.
8. Alnemri E.S., Livingston D.J., Nicholson D.W., Salvesen G., Thornberry N.A., Wong W.W., Yuan J. Human ICE/CED-3 protease nomenclature. Cell 1996, 87:171.
9. Alnylam Pharmaceuticals, Inc., 2011. News Release: Alnylam Launches " Alnylam 5×15" Product Strategy and Provides Guidance and Goals for 2011. Retrieved May 3, 2011 from http://phx.corporate-ir.net/phoenix.zhtml%3Fc=148005%26p=irol-newsArticle%26ID=1513530%26highlight=.
10. Alzheimer's Association, 2010. Changing the Trajectory of Alzheimer's Disease: A National Imperative. Retrieved April 20, 2011 from http://www.alz.org/trajectory.
11. Ambrose C.M., Duyao M.P., Barnes G., Bates G.P., Lin C.S., Srinidhi J., Baxendale S., Hummerich H., Lehrach H., Altherr M., et al. Structure and expression of the Huntington's disease gene: evidence against simple inactivation due to an expanded CAG repeat. Somatic Cell and Molecular Genetics 1994, 20:27-38.
12. Andrade M.A., Bork P. HEAT repeats in the Huntington's disease protein. Nature Genetics 1995, 11:115-116.
13. Aziz N.A., van der Burg J.M., Landwehrmeyer G.B., Brundin P., Stijnen T., Roos R.A. Weight loss in Huntington disease increases with higher CAG repeat number. Neurology 2008, 71:1506-1513.
14. Bates G. Huntingtin aggregation and toxicity in Huntington's disease. Lancet 2003, 361:1642-1644.
15. Behrens P.F., Franz P., Woodman B., Lindenberg K.S., Landwehrmeyer G.B. Impaired glutamate transport and glutamate-glutamine cycling: downstream effects of the Huntington mutation. Brain 2002, 125:1908-1922.
16. Benarroch E.E. NMDA receptors: recent insights and clinical correlations. Neurology 2011, 76:1750-1757.
17. Benchoua A., Trioulier Y., Zala D., Gaillard M.C., Lefort N., Dufour N., Saudou F., Elalouf J.M., Hirsch E., Hantraye P., Deglon N., Brouillet E. Involvement of mitochondrial complex II defects in neuronal death produced by N-terminus fragment of mutated huntingtin. Molecular Biology of the Cell 2006, 17:1652-1663.
18. Bilney B., Morris M.E., Perry A. Effectiveness of physiotherapy, occupational therapy, and speech pathology for people with Huntington's disease: a systematic review. Neurorehabilitation & Neural Repair. 2003, 17:12-24.
19. Blum L.C., Reymond J.L. 970 million druglike small molecules for virtual screening in the chemical universe database GDB-13. Journal of American Chemical Society 2009, 131:8732-8733.
20. Boldin M.P., Goncharov T.M., Goltsev Y.V., Wallach D. Involvement of MACH, a novel MORT1/FADD-interacting protease, in Fas/APO-1- and TNF receptor-induced cell death. Cell 1996, 85:803-815.
21. Bollag G., Hirth P., Tsai J., Zhang J., Ibrahim P.N., Cho H., Spevak W., Zhang C., Zhang Y., Habets G., Burton E.A., Wong B., Tsang G., West B.L., Powell B., Shellooe R., Marimuthu A., Nguyen H., Zhang K.Y., Artis D.R., Schlessinger J., Su F., Higgins B., Iyer R., D'Andrea K., Koehler A., Stumm M., Lin P.S., Lee R.J., Grippo J., Puzanov I., Kim K.B., Ribas A., McArthur G.A., Sosman J.A., Chapman P.B., Flaherty K.T., Xu X., Nathanson K.L., Nolop K. Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma. Nature 2010, 467:596-599.
22. Bonelli R.M., Wenning G.K. Pharmacological management of Huntington's disease: an evidence-based review. Current Pharmaceutical Design 2006, 12:2701-2720.
23. Borrell-Pages M., Canals J.M., Cordelieres F.P., Parker J.A., Pineda J.R., Grange G., Bryson E.A., Guillermier M., Hirsch E., Hantraye P., Cheetham M.E., Neri C., Alberch J., Brouillet E., Saudou F., Humbert S. Cystamine and cysteamine increase brain levels of BDNF in Huntington disease via HSJ1b and transglutaminase. Journal of Clinical Investigation 2006, 116:1410-1424.
24. Brett T.J., Legendre-Guillemin V., McPherson P.S., Fremont D.H. Structural definition of the F-actin-binding THATCH domain from HIP1R. Nature Structural & Molecular Biology 2006, 13:121-130.
25. Brouillet E., Hantraye P., Ferrante R.J., Dolan R., Leroy-Willig A., Kowall N.W., Beal M.F. Chronic mitochondrial energy impairment produces selective striatal degeneration and abnormal choreiform movements in primates. Proceedings of the National Academy of Sciences United States of America 1995, 92:7105-7109.
26. Browne S.E., Bowling A.C., MacGarvey U., Baik M.J., Berger S.C., Muqit M.M., Bird E.D., Beal M.F. Oxidative damage and metabolic dysfunction in Huntington's disease: selective vulnerability of the basal ganglia. Annals of Neurology 1997, 41:646-653.
27. Campesan S., Green E.W., Breda C., Sathyasaikumar K.V., Muchowski P.J., Schwarcz R., Kyriacou C.P., Giorgini F. The kynurenine pathway modulates neurodegeneration in a Drosophila model of Huntington's disease. Current Biology 2011, 21:961-966.
28. Carr R.A., Congreve M., Murray C.W., Rees D.C. Fragment-based lead discovery: leads by design. Drug Discovery Today 2005, 10:987-992.
29. Carroll J.B., Warby S.C., Southwell A.L., Doty C.N., Greenlee S., Skotte N., Hung G., Bennett C.F., Freier S.M., Hayden M.R. Potent and selective antisense oligonucleotides targeting single-nucleotide polymorphisms in the Huntington disease gene/allele-specific silencing of mutant huntingtin. Molecular Therapy 2011, 19:2178-2185.
30. Chen M., Ona V.O., Li M., Ferrante R.J., Fink K.B., Zhu S., Bian J., Guo L., Farrell L.A., Hersch S.M., Hobbs W., Vonsattel J.P., Cha J.H., Friedlander R.M. Minocycline inhibits caspase-1 and caspase-3 expression and delays mortality in a transgenic mouse model of Huntington disease. Nature Medicine 2000, 6:797-801.
31. Chen-Plotkin A.S., Sadri-Vakili G., Yohrling G.J., Braveman M.W., Benn C.L., Glajch K.E., DiRocco D.P., Farrell L.A., Krainc D., Gines S., MacDonald M.E., Cha J.H. Decreased association of the transcription factor Sp1 with genes downregulated in Huntington's disease. Neurobiology of Disease 2006, 22:233-241.
32. Choi S.A., Kim S.J., Chung K.C. Huntingtin-interacting protein 1-mediated neuronal cell death occurs through intrinsic apoptotic pathways and mitochondrial alterations. FEBS Letters 2006, 580:5275-5282.
33. Choo Y.S., Johnson G.V., MacDonald M., Detloff P.J., Lesort M. Mutant huntingtin directly increases susceptibility of mitochondria to the calcium-induced permeability transition and cytochrome c release. Human Molecular Genetics 2004, 13:1407-1420.
34. Choong I.C., Lew W., Lee D., Pham P., Burdett M.T., Lam J.W., Wiesmann C., Luong T.N., Fahr B., DeLano W.L., McDowell R.S., Allen D.A., Erlanson D.A., Gordon E.M., O'Brien T. Identification of potent and selective small-molecule inhibitors of caspase-3 through the use of extended tethering and structure-based drug design. Journal of Medicinal Chemistry 2002, 45:5005-5022.
35. Chu W., Rothfuss J., Chu Y., Zhou D., Mach R.H. Synthesis and in vitro evaluation of sulfonamide isatin Michael acceptors as small molecule inhibitors of caspase-6. Journal of Medicinal Chemistry 2009, 52:2188-2191.
36. Cingolani G., Petosa C., Weis K., Muller C.W. Structure of importin-beta bound to the IBB domain of importin-alpha. Nature 1999, 399:221-229.
37. ClinicalTrials.gov, 2012. CIT-HD. Study in Huntington's Disease. Retrieved February 15, 2012 from http://clinicaltrials.gov/ct2/show/study/NCT00271596%3Fcond=Huntington%26intr=citalopram%26rank=1.
38. Collins S., Meyer T. Cell biology: a sensor for calcium uptake. Nature 2010, 467:283.
39. Congreve M., Aharony D., Albert J., Callaghan O., Campbell J., Carr R.A., Chessari G., Cowan S., Edwards P.D., Frederickson M., McMenamin R., Murray C.W., Patel S., Wallis N. Application of fragment screening by X-ray crystallography to the discovery of aminopyridines as inhibitors of beta-secretase. Journal of Medicinal Chemistry 2007, 50:1124-1132.
40. Crawford E.D., Wells J.A. Caspase substrates and cellular remodeling. Annual Review of Biochemistry 2011, 80:1055-1087.
41. Crouch P.J., Savva M.S., Hung L.W., Donnelly P.S., Mot A.I., Parker S.J., Greenough M.A., Volitakis I., Adlard P.A., Cherny R.A., Masters C.L., Bush A.I., Barnham K.J., White A.R. The Alzheimer's therapeutic PBT2 promotes amyloid-beta degradation and GSK3 phosphorylation via a metal chaperone activity. Journal of Neurochemistry 2011, 119:220-230.
42. Cuervo A.M., Dice J.F. A receptor for the selective uptake and degradation of proteins by lysosomes. Science 1996, 273:501-503.
43. Cui L., Jeong H., Borovecki F., Parkhurst C.N., Tanese N., Krainc D. Transcriptional repression of PGC-1alpha by mutant huntingtin leads to mitochondrial dysfunction and neurodegeneration. Cell 2006, 127:59-69.
44. Darnell G., Orgel J.P., Pahl R., Meredith S.C. Flanking polyproline sequences inhibit beta-sheet structure in polyglutamine segments by inducing PPII-like helix structure. Journal of Molecular Biology 2007, 374:688-704.
45. De Rooij K.E., De Koning Gans P.A., Skraastad M.I., Belfroid R.D., Vegter-Van Der Vlis M., Roos R.A., Bakker E., Van Ommen G.J., Den Dunnen J.T., Losekoot M. Dynamic mutation in Dutch Huntington's disease patients: increased paternal repeat instability extending to within the normal size range. Journal of Medical Genetics 1993, 30:996-1002.
46. de Yebenes J.G., Landwehrmeyer B., Squitieri F., Reilmann R., Rosser A., Barker R.A., Saft C., Magnet M.K., Sword A., Rembratt A., Tedroff J. Pridopidine for the treatment of motor function in patients with Huntington's disease (MermaiHD): a phase 3, randomised, double-blind, placebo-controlled trial. The Lancet Neurology 2011, 10:1049-1057.
47. Dedeoglu A., Kubilus J.K., Yang L., Ferrante K.L., Hersch S.M., Beal M.F., Ferrante R.J. Creatine therapy provides neuroprotection after onset of clinical symptoms in Huntington's disease transgenic mice. Journal of Neurochemistry 2003, 85:1359-1367.
48. Degterev A., Huang Z., Boyce M., Li Y., Jagtap P., Mizushima N., Cuny G.D., Mitchison T.J., Moskowitz M.A., Yuan J. Chemical inhibitor of nonapoptotic cell death with therapeutic potential for ischemic brain injury. Nature Chemical Biology 2005, 1:112-119.
49. Dice J.F. Peptide sequences that target cytosolic proteins for lysosomal proteolysis. Trends in Biochemical Sciences 1990, 15:305-309.
50. DiFiglia M., Sapp E., Chase K.O., Davies S.W., Bates G.P., Vonsattel J.P., Aronin N. Aggregation of huntingtin in neuronal intranuclear inclusions and dystrophic neurites in brain. Science 1997, 277:1990-1993.
51. DiFiglia M., Sena-Esteves M., Chase K., Sapp E., Pfister E., Sass M., Yoder J., Reeves P., Pandey R.K., Rajeev K.G., Manoharan M., Sah D.W., Zamore P.D., Aronin N. Therapeutic silencing of mutant huntingtin with siRNA attenuates striatal and cortical neuropathology and behavioral deficits. Proceedings of the National Academy of Sciences United States of America 2007, 104:17204-17209.
52. Dixon S.J., Lemberg K.M., Lamprecht M.R., Skouta R., Zaitsev E.M., Gleason C.E., Patel D.N., Bauer A.J., Cantley A.M., Yang W.S., Morrison B., Stockwell B.R. Ferroptosis: an iron-dependent form of non-apoptotic cell death. Cell 2012, 149:1060-1072.
53. Djousse L., Knowlton B., Cupples L.A., Marder K., Shoulson I., Myers R.H. Weight loss in early stage of Huntington's disease. Neurology 2002, 59:1325-1330.
54. Dunah A.W., Jeong H., Griffin A., Kim Y.M., Standaert D.G., Hersch S.M., Mouradian M.M., Young A.B., Tanese N., Krainc D. Sp1 and TAFII130 transcriptional activity disrupted in early Huntington's disease. Science 2002, 296:2238-2243.
55. Duyao M.P., Auerbach A.B., Ryan A., Persichetti F., Barnes G.T., McNeil S.M., Ge P., Vonsattel J.P., Gusella J.F., Joyner A.L., et al. Inactivation of the mouse Huntington's disease gene homolog Hdh. Science 1995, 269:407-410.
56. Earnshaw W.C., Martins L.M., Kaufmann S.H. Mammalian caspases: structure, activation, substrates, and functions during apoptosis. Annual Review of Biochemistry 1999, 68:383-424.
57. Edison Pharmaceuticals Inc, 2011. Technology. Retrieved April 20, 2011 from edisonpharma.com/RnD.aspx.
58. Edwards P.D., Albert J.S., Sylvester M., Aharony D., Andisik D., Callaghan O., Campbell J.B., Carr R.A., Chessari G., Congreve M., Frederickson M., Folmer R.H., Geschwindner S., Koether G., Kolmodin K., Krumrine J., Mauger R.C., Murray C.W., Olsson L.L., Patel S., Spear N., Tian G. Application of fragment-based lead generation to the discovery of novel, cyclic amidine beta-secretase inhibitors with nanomolar potency, cellular activity, and high ligand efficiency. Journal of Medicinal Chemistry 2007, 50:5912-5925.
59. Ehrnhoefer D.E., Duennwald M., Markovic P., Wacker J.L., Engemann S., Roark M., Legleiter J., Marsh J.L., Thompson L.M., Lindquist S., Muchowski P.J., Wanker E.E. Green tea (-)-epigallocatechin-gallate modulates early events in huntingtin misfolding and reduces toxicity in Huntington's disease models. Human Molecular Genetics 2006, 15:2743-2751.
60. Ellgaard L., Ruddock L.W. The human protein disulphide isomerase family: substrate interactions and functional properties. EMBO Reports 2005, 6:28-32.
61. Enns G.M., Kinsman S.L., Perlman S.L., Spicer K.M., Abdenur J.E., Cohen B.H., Amagata A., Barnes A., Kheifets V., Shrader W.D., Thoolen M., Blankenberg F., Miller G. Initial experience in the treatment of inherited mitochondrial disease with EPI-743. Molecular Genetics and Metabolism 2012, 105:91-102.
62. Erlanson D.A., Braisted A.C., Raphael D.R., Randal M., Stroud R.M., Gordon E.M., Wells J.A. Site-directed ligand discovery. Proceedings of the National Academy of Sciences United States of America 2000, 97:9367-9372.
63. Erlanson D.A. Fragment-based lead discovery: a chemical update. Current Opinion in Biotechnology 2006, 17:643-652.
64. Erlanson D.A. Introduction to fragment-based drug discovery. Topics in Current Chemistry 2012, 317:1-32.
65. Estrada-Sanchez A.M., Montiel T., Segovia J., Massieu L. Glutamate toxicity in the striatum of the R6/2 Huntington's disease transgenic mice is age-dependent and correlates with decreased levels of glutamate transporters. Neurobiology of Disease 2009, 34:78-86.
66. Ferrante R.J., Andreassen O.A., Jenkins B.G., Dedeoglu A., Kuemmerle S., Kubilus J.K., Kaddurah-Daouk R., Hersch S.M., Beal M.F. Neuroprotective effects of creatine in a transgenic mouse model of Huntington's disease. Journal of Neuroscience 2000, 20:4389-4397.
67. Fischer M., Hubbard R.E. Fragment-based ligand discovery. Molecular Interventions 2009, 9:22-30.
68. Ford M.G., Pearse B.M., Higgins M.K., Vallis Y., Owen D.J., Gibson A., Hopkins C.R., Evans P.R., McMahon H.T. Simultaneous binding of PtdIns(4,5)P2 and clathrin by AP180 in the nucleation of clathrin lattices on membranes. Science 2001, 291:1051-1055.
69. Ford M.G., Mills I.G., Peter B.J., Vallis Y., Praefcke G.J., Evans P.R., McMahon H.T. Curvature of clathrin-coated pits driven by epsin. Nature 2002, 419:361-366.
70. Foroud T., Gray J., Ivashina J., Conneally P.M. Differences in duration of Huntington's disease based on age at onset. Journal of Neurology, Neurosurgery & Psychiatry. 1999, 66:52-56.
71. Gagnon K.T., Pendergraff H.M., Deleavey G.F., Swayze E.E., Potier P., Randolph J., Roesch E.B., Chattopadhyaya J., Damha M.J., Bennett C.F., Montaillier C., Lemaitre M., Corey D.R. Allele-selective inhibition of mutant huntingtin expression with antisense oligonucleotides targeting the expanded CAG repeat. Biochemistry 2010, 49:10166-10178.
72. Gal S., Zheng H., Fridkin M., Youdim M.B. Novel multifunctional neuroprotective iron chelator-monoamine oxidase inhibitor drugs for neurodegenerative diseases. In vivo selective brain monoamine oxidase inhibition and prevention of MPTP-induced striatal dopamine depletion. Journal of Neurochemistry 2005, 95:79-88.
73. Galluzzi L., Vitale I., Abrams J.M., Alnemri E.S., Baehrecke E.H., Blagosklonny M.V., Dawson T.M., Dawson V.L., El-Deiry W.S., Fulda S., Gottlieb E., Green D.R., Hengartner M.O., Kepp O., Knight R.A., Kumar S., Lipton S.A., Lu X., Madeo F., Malorni W., Mehlen P., Nunez G., Peter M.E., Piacentini M., Rubinsztein D.C., Shi Y., Simon H.U., Vandenabeele P., White E., Yuan J., Zhivotovsky B., Melino G., Kroemer G. Molecular definitions of cell death subroutines: recommendations of the Nomenclature Committee on Cell Death 2012. Cell Death & Differentiation 2012, 19:107-120.
74. Gauthier L.R., Charrin B.C., Borrell-Pages M., Dompierre J.P., Rangone H., Cordelieres F.P., De Mey J., MacDonald M.E., Lessmann V., Humbert S., Saudou F. Huntingtin controls neurotrophic support and survival of neurons by enhancing BDNF vesicular transport along microtubules. Cell 2004, 118:127-138.
75. Genervon Biopharmaceuticals, LLC, 2012. Pipeline. Retrieved February 5, 2012 from http://www.genervon.com/genervon/medicines_pipeline.php.
76. Gervais F.G., Singaraja R., Xanthoudakis S., Gutekunst C.A., Leavitt B.R., Metzler M., Hackam A.S., Tam J., Vaillancourt J.P., Houtzager V., Rasper D.M., Roy S., Hayden M.R., Nicholson D.W. Recruitment and activation of caspase-8 by the Huntingtin-interacting protein Hip-1 and a novel partner Hippi. Nature Cell Biology 2002, 4:95-105.
77. Geschwindner S., Olsson L.L., Albert J.S., Deinum J., Edwards P.D., de Beer T., Folmer R.H. Discovery of a novel warhead against beta-secretase through fragment-based lead generation. Journal of Medicinal Chemistry 2007, 50:5903-5911.
78. Gibrat C., Cicchetti F. Potential of cystamine and cysteamine in the treatment of neurodegenerative diseases. Progress in Neuro-Psychopharmacology & Biological Psychiatry 2011, 35:380-389.
79. Gleyzer N., Vercauteren K., Scarpulla R.C. Control of mitochondrial transcription specificity factors (TFB1M and TFB2M) by nuclear respiratory factors (NRF-1 and NRF-2) and PGC-1 family coactivators. Molecular and Cellular Biology 2005, 25:1354-1366.
80. Goffredo D., Rigamonti D., Zuccato C., Tartari M., Valenza M., Cattaneo E. Prevention of cytosolic IAPs degradation: a potential pharmacological target in Huntington's Disease. Pharmacological Research 2005, 52:140-150.
81. Goldberg Y.P., Andrew S.E., Theilmann J., Kremer B., Squitieri F., Telenius H., Brown J.D., Hayden M.R. Familial predisposition to recurrent mutations causing Huntington's disease: genetic risk to sibs of sporadic cases. Journal of Medical Genetics 1993, 30:987-990.
82. Goldberg Y.P., Nicholson D.W., Rasper D.M., Kalchman M.A., Koide H.B., Graham R.K., Bromm M., Kazemi-Esfarjani P., Thornberry N.A., Vaillancourt J.P., Hayden M.R. Cleavage of huntingtin by apopain, a proapoptotic cysteine protease, is modulated by the polyglutamine tract. Nature Genetics 1996, 13:442-449.
83. Graham R.K., Deng Y., Slow E.J., Haigh B., Bissada N., Lu G., Pearson J., Shehadeh J., Bertram L., Murphy Z., Warby S.C., Doty C.N., Roy S., Wellington C.L., Leavitt B.R., Raymond L.A., Nicholson D.W., Hayden M.R. Cleavage at the caspase-6 site is required for neuronal dysfunction and degeneration due to mutant huntingtin. Cell 2006, 125:1179-1191.
84. Graham R.K., Deng Y., Carroll J., Vaid K., Cowan C., Pouladi M.A., Metzler M., Bissada N., Wang L., Faull R.L., Gray M., Yang X.W., Raymond L.A., Hayden M.R. Cleavage at the 586 amino acid caspase-6 site in mutant huntingtin influences caspase-6 activation in vivo. Journal of Neuroscience 2010, 30:15019-15029.
85. Gray S.G. Targeting histone deacetylases for the treatment of Huntington's disease. CNS Neuroscience & Therapeutics 2010, 16:348-361.
86. Groves M.R., Hanlon N., Turowski P., Hemmings B.A., Barford D. The structure of the protein phosphatase 2A PR65/A subunit reveals the conformation of its 15 tandemly repeated HEAT motifs. Cell 1999, 96:99-110.
87. Gu M., Gash M.T., Mann V.M., Javoy-Agid F., Cooper J.M., Schapira A.H. Mitochondrial defect in Huntington's disease caudate nucleus. Annals of Neurology 1996, 39:385-389.
88. Hackam A.S., Yassa A.S., Singaraja R., Metzler M., Gutekunst C.A., Gan L., Warby S., Wellington C.L., Vaillancourt J., Chen N., Gervais F.G., Raymond L., Nicholson D.W., Hayden M.R. Huntingtin interacting protein 1 induces apoptosis via a novel caspase-dependent death effector domain. Journal of Biological Chemistry 2000, 275:41299-41308.
89. Hajduk P.J., Greer J. A decade of fragment-based drug design: strategic advances and lessons learned. Nature Reviews Drug Discovery 2007, 6:211-219.
90. Hann M.M., Leach A.R., Harper G. Molecular complexity and its impact on the probability of finding leads for drug discovery. Journal of Chemical Information and Computer Science 2001, 41:856-864.
91. Hara T., Nakamura K., Matsui M., Yamamoto A., Nakahara Y., Suzuki-Migishima R., Yokoyama M., Mishima K., Saito I., Okano H., Mizushima N. Suppression of basal autophagy in neural cells causes neurodegenerative disease in mice. Nature 2006, 441:885-889.
92. Hara M.R., Snyder S.H. Cell signaling and neuronal death. Annual Review of Pharmacology and Toxicology 2007, 47:117-141.
93. Harper P.S. The epidemiology of Huntington's disease. Human Genetics 1992, 89:365-376.
94. Harper S.Q., Staber P.D., He X., Eliason S.L., Martins I.H., Mao Q., Yang L., Kotin R.M., Paulson H.L., Davidson B.L. RNA interference improves motor and neuropathological abnormalities in a Huntington's disease mouse model. Proceedings of the National Academy of Sciences United States of America 2005, 102:5820-5825.
95. Hassel B., Tessler S., Faull R.L., Emson P.C. Glutamate uptake is reduced in prefrontal cortex in Huntington's disease. Neurochemical Research 2008, 33:232-237.
96. Hatahet F., Ruddock L.W. Protein disulfide isomerase: a critical evaluation of its function in disulfide bond formation. Antioxidants & Redox Signaling 2009, 11:2807-2850.
97. Hayden M.R., Beighton P. Genetic aspects of Huntington's chorea: results of a national survey. American Journal of Medical Genetics 1982, 11:135-141.
98. Hayden M.R., Leavitt B.R., Yasothan U., Kirkpatrick P. Tetrabenazine. Nature Reviews Drug Discovery 2009, 8:17-18.
99. Hebert L.E., Beckett L.A., Scherr P.A., Evans D.A. Annual incidence of Alzheimer disease in the United States projected to the years 2000 through 2050. Alzheimer Disease & Associated Disorders 2001, 15:169-173.
100. Hendricks A.E., Latourelle J.C., Lunetta K.L., Cupples L.A., Wheeler V., MacDonald M.E., Gusella J.F., Myers R.H. Estimating the probability of de novo HD cases from transmissions of expanded penetrant CAG alleles in the Huntington disease gene from male carriers of high normal alleles (27-35 CAG). American Journal of Medical Genetics A 2009, 149A:1375-1381.
101. Heng M.Y., Detloff P.J., Wang P.L., Tsien J.Z., Albin R.L. In vivo evidence for NMDA receptor-mediated excitotoxicity in a murine genetic model of Huntington disease. Journal of Neuroscience 2009, 29:3200-3205.
102. Hersch S.M., Gevorkian S., Marder K., Moskowitz C., Feigin A., Cox M., Como P., Zimmerman C., Lin M., Zhang L., Ulug A.M., Beal M.F., Matson W., Bogdanov M., Ebbel E., Zaleta A., Kaneko Y., Jenkins B., Hevelone N., Zhang H., Yu H., Schoenfeld D., Ferrante R., Rosas H.D. Creatine in Huntington disease is safe, tolerable, bioavailable in brain and reduces serum 8OH2'Dg. Neurology 2006, 66:250-252.
103. Hickey M.A., Chesselet M.F. Apoptosis in Huntington's disease. Progress in Neuro-Psychopharmacology & Biological Psychiatry 2003, 27:255-265.
104. Hoffstrom B.G., Kaplan A., Letso R., Schmid R.S., Turmel G.J., Lo D.C., Stockwell B.R. Inhibitors of protein disulfide isomerase suppress apoptosis induced by misfolded proteins. Nature Chemical Biology 2010, 6:900-906.
105. Huang K., Kang M.H., Askew C., Kang R., Sanders S.S., Wan J., Davis N.G., Hayden M.R. Palmitoylation and function of glial glutamate transporter-1 is reduced in the YAC128 mouse model of Huntington disease. Neurobiology of Disease 2010, 40:207-215.
106. Huntington G. On Chorea. The Medical and Surgical Reporter: A Weekly Journal 1872, 26:317-321.
107. Huntington G. On chorea. George Huntington, M.D. Journal of Neuropsychiatry & Clinical Neurosciences 2003, 15:109-112.
108. Huntington Study Group Pre2CARE Investigators, 2010. Safety and tolerability of high-dosage coenzyme Q10 in Huntington's disease and healthy subjects. Movement Disorders 25, 1924-1928.
109. Hyun T.S., Rao D.S., Saint-Dic D., Michael L.E., Kumar P.D., Bradley S.V., Mizukami I.F., Oravecz-Wilson K.I., Ross T.S. HIP1 and HIP1r stabilize receptor tyrosine kinases and bind 3-phosphoinositides via epsin N-terminal homology domains. Journal of Biological Chemistry 2004, 279:14294-14306.
110. Imarisio S., Carmichael J., Korolchuk V., Chen C.W., Saiki S., Rose C., Krishna G., Davies J.E., Ttofi E., Underwood B.R., Rubinsztein D.C. Huntington's disease: from pathology and genetics to potential therapies. Biochemical Journal 2008, 412:191-209.
111. Isis Pharmaceuticals, Inc., 2011. Press Release. Isis and CHDI Foundation Renew Drug Development Collaboration for Huntington's Disease. Retrieved February 15, 2012 from http://ir.isispharm.com/phoenix.zhtml%3Fc=222170%26p=irol-newsArticle%26ID=1595491%26highlight=.
112. Iwata A., Christianson J.C., Bucci M., Ellerby L.M., Nukina N., Forno L.S., Kopito R.R. Increased susceptibility of cytoplasmic over nuclear polyglutamine aggregates to autophagic degradation. Proceedings of the National Academy of Sciences United States of America 2005, 102:13135-13140.
113. Jankovic J. Treatment of hyperkinetic movement disorders. The Lancet Neurology 2009, 8:844-856.
114. High Throughput Screening: Methods and Protocols 2002, Humana Press, Totowa, NJ. First ed. W.P. Janzen (Ed.).
115. Jia H., Pallos J., Jacques V., Lau A., Tang B., Cooper A., Syed A., Purcell J., Chen Y., Sharma S., Sangrey G.R., Darnell S.B., Plasterer H., Sadri-Vakili G., Gottesfeld J.M., Thompson L.M., Rusche J.R., Marsh J.L., Thomas E.A. Histone deacetylase (HDAC) inhibitors targeting HDAC3 and HDAC1 ameliorate polyglutamine-elicited phenotypes in model systems of Huntington's disease. Neurobiology of Disease 2012, 46:351-361.
116. Jorgensen J.R., Emerich D.F., Thanos C., Thompson L.H., Torp M., Bintz B., Fjord-Larsen L., Johansen T.E., Wahlberg L.U. Lentiviral delivery of meteorin protects striatal neurons against excitotoxicity and reverses motor deficits in the quinolinic acid rat model. Neurobiology of Disease 2011, 41:160-168.
117. Jummani R., Okun M. Sydenham chorea. Archives of Neurology 2001, 58:311-313.
118. Kalchman M.A., Koide H.B., McCutcheon K., Graham R.K., Nichol K., Nishiyama K., Kazemi-Esfarjani P., Lynn F.C., Wellington C., Metzler M., Goldberg Y.P., Kanazawa I., Gietz R.D., Hayden M.R. HIP1, a human homologue of S. cerevisiae Sla2p, interacts with membrane-associated huntingtin in the brain. Nature Genetics 1997, 16:44-53.
119. Kandil M.R., Tohamy S.A., Fattah M.A., Ahmed H.N., Farwiez H.M. Prevalence of chorea, dystonia and athetosis in Assiut, Egypt: a clinical and epidemiological study. Neuroepidemiology 1994, 13:202-210.
120. Kerr J.F., Wyllie A.H., Currie A.R. Apoptosis: a basic biological phenomenon with wide-ranging implications in tissue kinetics. British Journal of Cancer 1972, 26:239-257.
121. Kiechle T., Dedeoglu A., Kubilus J., Kowall N.W., Beal M.F., Friedlander R.M., Hersch S.M., Ferrante R.J. Cytochrome C and caspase-9 expression in Huntington's disease. Neuromolecular Medicine 2002, 1:183-195.
122. Kim J., Moody J.P., Edgerly C.K., Bordiuk O.L., Cormier K., Smith K., Beal M.F., Ferrante R.J. Mitochondrial loss, dysfunction and altered dynamics in Huntington's disease. Human Molecular Genetics 2010, 19:3919-3935.
123. Kim M.W., Chelliah Y., Kim S.W., Otwinowski Z., Bezprozvanny I. Secondary structure of Huntingtin amino-terminal region. Structure 2009, 17:1205-1212.
124. Kirkwood S.C., Su J.L., Conneally P., Foroud T. Progression of symptoms in the early and middle stages of Huntington disease. Archives of Neurology 2001, 58:273-278.
125. Klaiman G., Petzke T.L., Hammond J., Leblanc A.C. Targets of caspase-6 activity in human neurons and Alzheimer disease. Molecular & Cellular Proteomics 2008, 7:1541-1555.
126. Koroshetz W.J., Jenkins B.G., Rosen B.R., Beal M.F. Energy metabolism defects in Huntington's disease and effects of coenzyme Q10. Annals of Neurology 1997, 41:160-165.
127. Krack P. Relicts of dancing mania: the dancing procession of Echternach. Neurology 1999, 53:2169-2172.
128. Kremer B., Goldberg P., Andrew S.E., Theilmann J., Telenius H., Zeisler J., Squitieri F., Lin B., Bassett A., Almqvist E., et al. A worldwide study of the Huntington's disease mutation. The sensitivity and specificity of measuring CAG repeats. New England Journal of Medicine 1994, 330:1401-1406.
129. Kremer B., Almqvist E., Theilmann J., Spence N., Telenius H., Goldberg Y.P., Hayden M.R. Sex-dependent mechanisms for expansions and contractions of the CAG repeat on affected Huntington disease chromosomes. American Journal of Human Genetics 1995, 57:343-350.
130. Krier M., Bret G., Rognan D. Assessing the scaffold diversity of screening libraries. Journal of Chemical Information and Modeling 2006, 46:512-524.
131. Kroemer G., Galluzzi L., Vandenabeele P., Abrams J., Alnemri E.S., Baehrecke E.H., Blagosklonny M.V., El-Deiry W.S., Golstein P., Green D.R., Hengartner M., Knight R.A., Kumar S., Lipton S.A., Malorni W., Nunez G., Peter M.E., Tschopp J., Yuan J., Piacentini M., Zhivotovsky B., Melino G. Classification of cell death: recommendations of the Nomenclature Committee on Cell Death 2009. Cell Death & Differentiation 2009, 16:3-11.
132. Kuhl D.E., Phelps M.E., Markham C.H., Metter E.J., Riege W.H., Winter J. Cerebral metabolism and atrophy in Huntington's disease determined by 18FDG and computed tomographic scan. Annals of Neurology 1982, 12:425-434.
133. Kwok R.P., Lundblad J.R., Chrivia J.C., Richards J.P., Bachinger H.P., Brennan R.G., Roberts S.G., Green M.R., Goodman R.H. Nuclear protein CBP is a coactivator for the transcription factor CREB. Nature 1994, 370:223-226.
134. Lakhani S.A., Masud A., Kuida K., Porter G.A., Booth C.J., Mehal W.Z., Inayat I., Flavell R.A. Caspases 3 and 7: key mediators of mitochondrial events of apoptosis. Science 2006, 311:847-851.
135. Lamkanfi M., Kanneganti T.D., Van Damme P., Vanden Berghe T., Vanoverberghe I., Vandekerckhove J., Vandenabeele P., Gevaert K., Nunez G. Targeted peptidecentric proteomics reveals caspase-7 as a substrate of the caspase-1 inflammasomes. Molecular & Cellular Proteomics 2008, 7:2350-2363.
136. Langdon S.R., Brown N., Blagg J. Scaffold diversity of exemplified medicinal chemistry space. Journal of Chemical Information and Modeling 2011, 51:2174-2185.
137. Leach A.R., Hann M.M. Molecular complexity and fragment-based drug discovery: ten years on. Current Opinion in Chemical Biology 2011, 15:489-496.
138. Leavitt B.R., Guttman J.A., Hodgson J.G., Kimel G.H., Singaraja R., Vogl A.W., Hayden M.R. Wild-type huntingtin reduces the cellular toxicity of mutant huntingtin in vivo. American Journal of Human Genetics 2001, 68:313-324.
139. Leavitt B.R., van Raamsdonk J.M., Shehadeh J., Fernandes H., Murphy Z., Graham R.K., Wellington C.L., Raymond L.A., Hayden M.R. Wild-type huntingtin protects neurons from excitotoxicity. Journal of Neurochemistry 2006, 96:1121-1129.
140. Legendre-Guillemin V., Wasiak S., Hussain N.K., Angers A., McPherson P.S. ENTH/ANTH proteins and clathrin-mediated membrane budding. Journal of Cell Science 2004, 117:9-18.
141. Legendre-Guillemin V., Metzler M., Lemaire J.F., Philie J., Gan L., Hayden M.R., McPherson P.S. Huntingtin interacting protein 1 (HIP1) regulates clathrin assembly through direct binding to the regulatory region of the clathrin light chain. Journal of Biological Chemistry 2005, 280:6101-6108.
142. Leonard J.R., Klocke B.J., D'Sa C., Flavell R.A., Roth K.A. Strain-dependent neurodevelopmental abnormalities in caspase-3-deficient mice. Journal of Neuropathology & Experimental Neurology 2002, 61:673-677.
143. Levenga J., Hayashi S., de Vrij F.M., Koekkoek S.K., van der Linde H.C., Nieuwenhuizen I., Song C., Buijsen R.A., Pop A.S., Gomezmancilla B., Nelson D.L., Willemsen R., Gasparini F., Oostra B.A. AFQ056, a new mGluR5 antagonist for treatment of fragile X syndrome. Neurobiology of Disease 2011, 42:311-317.
144. Leyva M.J., Degiacomo F., Kaltenbach L.S., Holcomb J., Zhang N., Gafni J., Park H., Lo D.C., Salvesen G.S., Ellerby L.M., Ellman J.A. Identification and evaluation of small molecule pan-caspase inhibitors in Huntington's disease models. Chemistry & Biology 2010, 17:1189-1200.
145. Li S.H., Cheng A.L., Zhou H., Lam S., Rao M., Li H., Li X.J. Interaction of Huntington disease protein with transcriptional activator Sp1. Molecular and Cellular Biology 2002, 22:1277-1287.
146. Li W., Serpell L.C., Carter W.J., Rubinsztein D.C., Huntington J.A. Expression and characterization of full-length human huntingtin, an elongated HEAT repeat protein. Journal of Biological Chemistry 2006, 281:15916-15922.
147. Lievens J.C., Woodman B., Mahal A., Spasic-Boscovic O., Samuel D., Kerkerian-Le Goff L., Bates G.P. Impaired glutamate uptake in the R6 Huntington's disease transgenic mice. Neurobiology of Disease 2001, 8:807-821.
148. Lin B., Rommens J.M., Graham R.K., Kalchman M., MacDonald H., Nasir J., Delaney A., Goldberg Y.P., Hayden M.R. Differential 3' polyadenylation of the Huntington disease gene results in two mRNA species with variable tissue expression. Human Molecular Genetics 1993, 2:1541-1545.
149. Link Medicine, 2012. Our Approach. Retrieved February 7, 2012 from http://www.linkmedicine.com/science/approach.asp.
150. Lipkus A.H., Yuan Q., Lucas K.A., Funk S.A., Bartelt W.F., Schenck R.J., Trippe A.J. Structural diversity of organic chemistry. A scaffold analysis of the CAS Registry. Journal of Organic Chemistry 2008, 73:4443-4451.
151. Liu Z., Meray R.K., Grammatopoulos T.N., Fredenburg R.A., Cookson M.R., Liu Y., Logan T., Lansbury P.T. Membrane-associated farnesylated UCH-L1 promotes alpha-synuclein neurotoxicity and is a therapeutic target for Parkinson's disease. Proceedings of the National Academy of Sciences United States of America 2009, 106:4635-4640.
152. Lobo M.K. Molecular profiling of striatonigral and striatopallidal medium spiny neurons past, present, and future. International Review of Neurobiology 2009, 89:1-35.
153. Lodi R., Schapira A.H., Manners D., Styles P., Wood N.W., Taylor D.J., Warner T.T. Abnormal in vivo skeletal muscle energy metabolism in Huntington's disease and dentatorubropallidoluysian atrophy. Annals of Neurology 2000, 48:72-76.
154. Lucetti C., Del Dotto P., Gambaccini G., Dell' Agnello G., Bernardini S., Rossi G., Murri L., Bonuccelli U. IV amantadine improves chorea in Huntington's disease: an acute randomized, controlled study. Neurology 2003, 60:1995-1997.
155. Lundin A., Dietrichs E., Haghighi S., Goller M.L., Heiberg A., Loutfi G., Widner H., Wiktorin K., Wiklund L., Svenningsson A., Sonesson C., Waters N., Waters S., Tedroff J. Efficacy and safety of the dopaminergic stabilizer Pridopidine (ACR16) in patients with Huntington's disease. Clinical Neuropharmacology 2010, 33:260-264.
156. Luthi-Carter R., Taylor D.M., Pallos J., Lambert E., Amore A., Parker A., Moffitt H., Smith D.L., Runne H., Gokce O., Kuhn A., Xiang Z., Maxwell M.M., Reeves S.A., Bates G.P., Neri C., Thompson L.M., Marsh J.L., Kazantsev A.G. SIRT2 inhibition achieves neuroprotection by decreasing sterol biosynthesis. Proceedings of the National Academy of Sciences 2010, 107:7927-8793.
157. Machida Y., Okada T., Kurosawa M., Oyama F., Ozawa K., Nukina N. rAAV-mediated shRNA ameliorated neuropathology in Huntington disease model mouse. Biochemical and Biophysical Research Communications 2006, 343:190-197.
158. Mann V.M., Cooper J.M., Javoy-Agid F., Agid Y., Jenner P., Schapira A.H. Mitochondrial function and parental sex effect in Huntington's disease. Lancet 1990, 336:749.
159. Martin W.R., Clark C., Ammann W., Stoessl A.J., Shtybel W., Hayden M.R. Cortical glucose metabolism in Huntington's disease. Neurology 1992, 42:223-229.
160. Martinez-Vicente M., Talloczy Z., Wong E., Tang G., Koga H., Kaushik S., de Vries R., Arias E., Harris S., Sulzer D., Cuervo A.M. Cargo recognition failure is responsible for inefficient autophagy in Huntington's disease. Nature Neuroscience 2010, 13:567-576.
161. Mazziotta J.C., Phelps M.E., Pahl J.J., Huang S.C., Baxter L.R., Riege W.H., Hoffman J.M., Kuhl D.E., Lanto A.B., Wapenski J.A., et al. Reduced cerebral glucose metabolism in asymptomatic subjects at risk for Huntington's disease. New England Journal of Medicine 1987, 316:357-362.
162. McMahon H.T., Boucrot E. Molecular mechanism and physiological functions of clathrin-mediated endocytosis. Nature Reviews Molecular and Cellular Biology 2011, 12:517-533.
163. McManus K.J., Hendzel M.J. CBP, a transcriptional coactivator and acetyltransferase. Biochemistry and Cell Biology 2001, 79:253-266.
164. Metzler M., Legendre-Guillemin V., Gan L., Chopra V., Kwok A., McPherson P.S., Hayden M.R. HIP1 functions in clathrin-mediated endocytosis through binding to clathrin and adaptor protein 2. Journal of Biological Chemistry 2001, 276:39271-39276.
165. Metzler M., Li B., Gan L., Georgiou J., Gutekunst C.A., Wang Y., Torre E., Devon R.S., Oh R., Legendre-Guillemin V., Rich M., Alvarez C., Gertsenstein M., McPherson P.S., Nagy A., Wang Y.T., Roder J.C., Raymond L.A., Hayden M.R. Disruption of the endocytic protein HIP1 results in neurological deficits and decreased AMPA receptor trafficking. EMBO Journal 2003, 22:3254-3266.
166. Metzler M., Gan L., Wong T.P., Liu L., Helm J., Georgiou J., Wang Y., Bissada N., Cheng K., Roder J.C., Wang Y.T., Hayden M.R. NMDA receptor function and NMDA receptor-dependent phosphorylation of huntingtin is altered by the endocytic protein HIP1. Journal of Neuroscience 2007, 27:2298-2308.
167. Miller B.R., Dorner J.L., Shou M., Sari Y., Barton S.J., Sengelaub D.R., Kennedy R.T., Rebec G.V. Up-regulation of GLT1 expression increases glutamate uptake and attenuates the Huntington's disease phenotype in the R6/2 mouse. Neuroscience 2008, 153:329-337.
168. Mills I.G., Gaughan L., Robson C., Ross T., McCracken S., Kelly J., Neal D.E. Huntingtin interacting protein 1 modulates the transcriptional activity of nuclear hormone receptors. Journal of Cell Biology 2005, 170:191-200.
169. Milnerwood A.J., Gladding C.M., Pouladi M.A., Kaufman A.M., Hines R.M., Boyd J.D., Ko R.W., Vasuta O.C., Graham R.K., Hayden M.R., Murphy T.H., Raymond L.A. Early increase in extrasynaptic NMDA receptor signaling and expression contributes to phenotype onset in Huntington's disease mice. Neuron 2010, 65:178-190.
170. Mink J.W. The basal ganglia: focused selection and inhibition of competing motor programs. Progress in Neurobiology 1996, 50:381-425.
171. Morfini G.A., You Y.M., Pollema S.L., Kaminska A., Liu K., Yoshioka K., Bjorkblom B., Coffey E.T., Bagnato C., Han D., Huang C.F., Banker G., Pigino G., Brady S.T. Pathogenic huntingtin inhibits fast axonal transport by activating JNK3 and phosphorylating kinesin. Nature Neuroscience 2009, 12:864-871.
172. Murray C.W., Callaghan O., Chessari G., Cleasby A., Congreve M., Frederickson M., Hartshorn M.J., McMenamin R., Patel S., Wallis N. Application of fragment screening by X-ray crystallography to beta-secretase. Journal of Medicinal Chemistry 2007, 50:1116-1123.
173. Murray C.W., Rees D.C. The rise of fragment-based drug discovery. Nature Chemistry 2009, 1:187-192.
174. Muzio M., Chinnaiyan A.M., Kischkel F.C., O'Rourke K., Shevchenko A., Ni J., Scaffidi C., Bretz J.D., Zhang M., Gentz R., Mann M., Krammer P.H., Peter M.E., Dixit V.M. FLICE, a novel FADD-homologous ICE/CED-3-like protease, is recruited to the CD95 (Fas/APO-1) death-inducing signaling complex. Cell 1996, 85:817-827.
175. Nakamura T., Wang L., Wong C.C., Scott F.L., Eckelman B.P., Han X., Tzitzilonis C., Meng F., Gu Z., Holland E.A., Clemente A.T., Okamoto S., Salvesen G.S., Riek R., Yates J.R., Lipton S.A. Transnitrosylation of XIAP regulates caspase-dependent neuronal cell death. Molecular Cell 2010, 39:184-195.
176. Nakashima K., Watanabe Y., Kusumi M., Nanba E., Maeoka Y., Nakagawa M., Igo M., Irie H., Ishino H., Fujimoto A., Goto J., Takahashi K. Epidemiological and genetic studies of Huntington's Disease in the San-in Area of Japan. Neuroepidemiology 1996, 15:126-131.
177. Nasir J., Floresco S.B., O'Kusky J.R., Diewert V.M., Richman J.M., Zeisler J., Borowski A., Marth J.D., Phillips A.G., Hayden M.R. Targeted disruption of the Huntington's disease gene results in embryonic lethality and behavioral and morphological changes in heterozygotes. Cell 1995, 81:811-823.
178. Neef D.W., Turski M.L., Thiele D.J. Modulation of heat shock transcription factor 1 as a therapeutic target for small molecule intervention in neurodegenerative disease. PLoS Biology 2010, 8:e1000291.
179. Neuralstem, Inc., 2011. Neuralstem Cell Therapy: Repairing and Replacing Damaged Cells Retrieved February 15, 2012 from http://www.neuralstem.com/cell-therapy.
180. Neurologix, Inc., 2011. Product Pipeline. Huntington's Disease. Retrieved February 5, 2012 from http://www.neurologix.net/products/huntingtons.html.
181. Nguyen T., Hamby A., Massa S.M. Clioquinol down-regulates mutant huntingtin expression in vitro and mitigates pathology in a Huntington's disease mouse model. Proceedings of the National Academy of Sciences United States of America 2005, 102:11840-11845.
182. Niu Q., Ybe J.A. Crystal structure at 2.8 A of Huntingtin-interacting protein 1 (HIP1) coiled-coil domain reveals a charged surface suitable for HIP1 protein interactor (HIPPI). Journal of Molecular Biology 2008, 375:1197-1205.
183. Nixon R.A., Wegiel J., Kumar A., Yu W.H., Peterhoff C., Cataldo A., Cuervo A.M. Extensive involvement of autophagy in Alzheimer disease: an immuno-electron microscopy study. Journal of Neuropathology & Experimental Neurology 2005, 64:113-122.
184. Nixon R.A. Autophagy in neurodegenerative disease: friend, foe or turncoat?. Trends in Neuroscience 2006, 29:528-535.
185. NsGene A/S, 2012. NsG33-Meteorin. Retrieved February 15, 2012 from http://nsgene.dk/NsGene-413.aspx.
186. Nucifora F.C., Sasaki M., Peters M.F., Huang H., Cooper J.K., Yamada M., Takahashi H., Tsuji S., Troncoso J., Dawson V.L., Dawson T.M., Ross C.A. Interference by huntingtin and atrophin-1 with cbp-mediated transcription leading to cellular toxicity. Science 2001, 291:2423-2428.
187. O'Brien T., Fahr B.T., Sopko M.M., Lam J.W., Waal N.D., Raimundo B.C., Purkey H.E., Pham P., Romanowski M.J. Structural analysis of caspase-1 inhibitors derived from Tethering. Acta Crystallographica Section F Structural Biology and Crystallization Communications 2005, 61:451-458.
188. Okamoto S., Pouladi M.A., Talantova M., Yao D., Xia P., Ehrnhoefer D.E., Zaidi R., Clemente A., Kaul M., Graham R.K., Zhang D., Vincent Chen H.S., Tong G., Hayden M.R., Lipton S.A. Balance between synaptic versus extrasynaptic NMDA receptor activity influences inclusions and neurotoxicity of mutant huntingtin. Nature Medicine 2009, 15:1407-1413.
189. O'Kusky J.R., Nasir J., Cicchetti F., Parent A., Hayden M.R. Neuronal degeneration in the basal ganglia and loss of pallido-subthalamic synapses in mice with targeted disruption of the Huntington's disease gene. Brain Research 1999, 818:468-479.
190. Ona V.O., Li M., Vonsattel J.P., Andrews L.J., Khan S.Q., Chung W.M., Frey A.S., Menon A.S., Li X.J., Stieg P.E., Yuan J., Penney J.B., Young A.B., Cha J.H., Friedlander R.M. Inhibition of caspase-1 slows disease progression in a mouse model of Huntington's disease. Nature 1999, 399:263-267.
191. Oryzon, 2012. Press Release 2012. Oryzon nominates bispecific LSD1/MAOB inhibitor as drug candidate to enter preclinical development in Huntington's Disease. Retrieved February 15, 2012 from http://www.oryzon.com/files/PRESS_RELEASE_2002-2012.pdf.
192. Osler, S.W., 1894. Historical note. Etiology, in: On Chorea and Choreiform Affections. H.K. Lewis, London, pp. 3-19.
193. Overholtzer M., Mailleux A.A., Mouneimne G., Normand G., Schnitt S.J., King R.W., Cibas E.S., Brugge J.S. A nonapoptotic cell death process, entosis, that occurs by cell-in-cell invasion. Cell 2007, 131:966-979.
194. Panov A.V., Gutekunst C.A., Leavitt B.R., Hayden M.R., Burke J.R., Strittmatter W.J., Greenamyre J.T. Early mitochondrial calcium defects in Huntington's disease are a direct effect of polyglutamines. Nature Neuroscience 2002, 5:731-736.
195. Park R.H., Park M.P. Saint Vitus' dance: vital misconceptions by Sydenham and Bruegel. Journal of Royal Society of Medicine 1990, 83:512-515.
196. Parker J.A., Metzler M., Georgiou J., Mage M., Roder J.C., Rose A.M., Hayden M.R., Neri C. Huntingtin-interacting protein 1 influences worm and mouse presynaptic function and protects Caenorhabditis elegans neurons against mutant polyglutamine toxicity. Journal of Neuroscience 2007, 27:11056-11064.
197. Perez-Navarro E., Akerud P., Marco S., Canals J.M., Tolosa E., Arenas E., Alberch J. Neurturin protects striatal projection neurons but not interneurons in a rat model of Huntington's disease. Neuroscience 2000, 98:89-96.
198. Phillips W., Shannon K.M., Barker R.A. The current clinical management of Huntington's disease. Movement Disorders 2008, 23:1491-1504.
199. Plexxikon, Inc., 2011. Oncology. Melanoma & BRAF Mutant Cancer Program. Retrieved August 30, 2011 from http://www.plexxikon.com/file.cfm/13/docs/Plexxikon_Melanoma_v15%203%20final_080211.pdf.
200. Powers W.J., Videen T.O., Markham J., McGee-Minnich L., Antenor-Dorsey J.V., Hershey T., Perlmutter J.S. Selective defect of in vivo glycolysis in early Huntington's disease striatum. Proceedings of the National Academy of Sciences United States of America 2007, 104:2945-2949.
201. Pratley R.E., Salbe A.D., Ravussin E., Caviness J.N. Higher sedentary energy expenditure in patients with Huntington's disease. Annals of Neurology 2000, 47:64-70.
202. Prosensa, 2012. HD-Huntington Disease. Retrieved February 16, 2012 from http://prosensa.eu/patients-and-family/huntington-disease.
203. Qin Z.H., Wang Y., Sapp E., Cuiffo B., Wanker E., Hayden M.R., Kegel K.B., Aronin N., DiFiglia M. Huntingtin bodies sequester vesicle-associated proteins by a polyproline-dependent interaction. Journal of Neuroscience 2004, 24:269-281.
204. Quarrell O.W., Rigby A.S., Barron L., Crow Y., Dalton A., Dennis N., Fryer A.E., Heydon F., Kinning E., Lashwood A., Losekoot M., Margerison L., McDonnell S., Morrison P.J., Norman A., Peterson M., Raymond F.L., Simpson S., Thompson E., Warner J. Reduced penetrance alleles for Huntington's disease: a multi-centre direct observational study. Journal of Medical Genetics 2007, 44:e68.
205. Ramaswamy S., McBride J.L., Herzog C.D., Brandon E., Gasmi M., Bartus R.T., Kordower J.H. Neurturin gene therapy improves motor function and prevents death of striatal neurons in a 3-nitropropionic acid rat model of Huntington's disease. Neurobiology of Disease 2007, 26:375-384.
206. Ramaswamy S., McBride J.L., Han I., Berry-Kravis E.M., Zhou L., Herzog C.D., Gasmi M., Bartus R.T., Kordower J.H. Intrastriatal CERE-120 (AAV-Neurturin) protects striatal and cortical neurons and delays motor deficits in a transgenic mouse model of Huntington's disease. Neurobiology of Disease 2009, 34:40-50.
207. Ravikumar B., Duden R., Rubinsztein D.C. Aggregate-prone proteins with polyglutamine and polyalanine expansions are degraded by autophagy. Human Molecular Genetics 2002, 11:1107-1117.
208. Ravikumar B., Vacher C., Berger Z., Davies J.E., Luo S., Oroz L.G., Scaravilli F., Easton D.F., Duden R., O'Kane C.J., Rubinsztein D.C. Inhibition of mTOR induces autophagy and reduces toxicity of polyglutamine expansions in fly and mouse models of Huntington disease. Nature Genetics 2004, 36:585-595.
209. Raymond L.A. Excitotoxicity in Huntington disease. Clinical Neuroscience Research 2003, 3:121-128.
210. Rees D.C., Congreve M., Murray C.W., Carr R. Fragment-based lead discovery. Nature Reviews Drug Discovery 2004, 3:660-672.
211. ReNeuron, 2011. ReNeuron presents further pre-clinical stem cell data at US conference. 27/10/04. Retrieved February 5, 2012 from http://www.reneuron.co.uk/monthly-archive/91-reneuron-presents-further-pre-clinical-stem-cell-data-at-us-conference-271004.
212. Rigamonti D., Bauer J.H., De-Fraja C., Conti L., Sipione S., Sciorati C., Clementi E., Hackam A., Hayden M.R., Li Y., Cooper J.K., Ross C.A., Govoni S., Vincenz C., Cattaneo E. Wild-type huntingtin protects from apoptosis upstream of caspase-3. Journal of Neuroscience 2000, 20:3705-3713.
213. Ross C.A., Tabrizi S.J. Huntington's disease: from molecular pathogenesis to clinical treatment. The Lancet Neurology 2011, 10:83-98.
214. Rothstein J.D., Patel S., Regan M.R., Haenggeli C., Huang Y.H., Bergles D.E., Jin L., Dykes Hoberg M., Vidensky S., Chung D.S., Toan S.V., Bruijn L.I., Su Z.Z., Gupta P., Fisher P.B. Beta-lactam antibiotics offer neuroprotection by increasing glutamate transporter expression. Nature 2005, 433:73-77.
215. Rubinsztein D.C., Leggo J., Coles R., Almqvist E., Biancalana V., Cassiman J.J., Chotai K., Connarty M., Crauford D., Curtis A., Curtis D., Davidson M.J., Differ A.M., Dode C., Dodge A., Frontali M., Ranen N.G., Stine O.C., Sherr M., Abbott M.H., Franz M.L., Graham C.A., Harper P.S., Hedreen J.C., Hayden M.R., et al. Phenotypic characterization of individuals with 30-40 CAG repeats in the Huntington disease (HD) gene reveals HD cases with 36 repeats and apparently normal elderly individuals with 36-39 repeats. American Journal of Human Genetics 1996, 59:16-22.
216. Ruchaud S., Korfali N., Villa P., Kottke T.J., Dingwall C., Kaufmann S.H., Earnshaw W.C. Caspase-6 gene disruption reveals a requirement for lamin A cleavage in apoptotic chromatin condensation. EMBO Journal 2002, 21:1967-1977.
217. Ruskin D.N., Ross J.L., Kawamura M., Ruiz T.L., Geiger J.D., Masino S.A. A ketogenic diet delays weight loss and does not impair working memory or motor function in the R6/2 1J mouse model of Huntington's disease. Physiology & Behavior 2011, 103:501-507.
218. Saft C., Zange J., Andrich J., Muller K., Lindenberg K., Landwehrmeyer B., Vorgerd M., Kraus P.H., Przuntek H., Schols L. Mitochondrial impairment in patients and asymptomatic mutation carriers of Huntington's disease. Movement Disorders 2005, 20:674-679.
219. Sanchez I., Xu C.J., Juo P., Kakizaka A., Blenis J., Yuan J. Caspase-8 is required for cell death induced by expanded polyglutamine repeats. Neuron 1999, 22:623-633.
220. Sari Y., Prieto A.L., Barton S.J., Miller B.R., Rebec G.V. Ceftriaxone-induced up-regulation of cortical and striatal GLT1 in the R6/2 model of Huntington's disease. Journal of Biomedical Science 2010, 17:62.
221. Saudou F., Finkbeiner S., Devys D., Greenberg M.E. Huntingtin acts in the nucleus to induce apoptosis but death does not correlate with the formation of intranuclear inclusions. Cell 1998, 95:55-66.
222. Saydoff J.A., Liu L.S., Garcia R.A., Hu Z., Li D., von Borstel R.W. Oral uridine pro-drug PN401 decreases neurodegeneration, behavioral impairment, weight loss and mortality in the 3-nitropropionic acid mitochondrial toxin model of Huntington's disease. Brain Research 2003, 994:44-54.
223. Saydoff J.A., Garcia R.A., Browne S.E., Liu L., Sheng J., Brenneman D., Hu Z., Cardin S., Gonzalez A., von Borstel R.W., Gregorio J., Burr H., Beal M.F. Oral uridine pro-drug PN401 is neuroprotective in the R6/2 and N171-82Q mouse models of Huntington's disease. Neurobiology of Disease 2006, 24:455-465.
224. Scarpulla R.C. Transcriptional paradigms in mammalian mitochondrial biogenesis and function. Physiological Reviews 2008, 88:611-638.
225. Schols L., Bauer P., Schmidt T., Schulte T., Riess O. Autosomal dominant cerebellar ataxias: clinical features, genetics, and pathogenesis. The Lancet Neurology 2004, 3:291-304.
226. Schuffenhauer A., Ruedisser S., Marzinzik A.L., Jahnke W., Blommers M., Selzer P., Jacoby E. Library design for fragment based screening. Current Topics in Medicinal Chemistry 2005, 5:751-762.
227. Scrimgeour E.M. Huntington's disease in Tanzania. Journal of Medical Genetics 1981, 18:200-203.
228. Shuker S.B., Hajduk P.J., Meadows R.P., Fesik S.W. Discovering high-affinity ligands for proteins: SAR by NMR. Science 1996, 274:1531-1534.
229. Simmons D.A., Rex C.S., Palmer L., Pandyarajan V., Fedulov V., Gall C.M., Lynch G. Up-regulating BDNF with an ampakine rescues synaptic plasticity and memory in Huntington's disease knockin mice. Proceedings of the National Academy of Sciences United States of America 2009, 106:4906-4911.
230. Simmons D.A., Mehta R.A., Lauterborn J.C., Gall C.M., Lynch G. Brief ampakine treatments slow the progression of Huntington's disease phenotypes in R6/2 mice. Neurobiology of Disease 2011, 41:436-444.
231. Singaraja R.R., Hadano S., Metzler M., Givan S., Wellington C.L., Warby S., Yanai A., Gutekunst C.A., Leavitt B.R., Yi H., Fichter K., Gan L., McCutcheon K., Chopra V., Michel J., Hersch S.M., Ikeda J.E., Hayden M.R. HIP14, a novel ankyrin domain-containing protein, links huntingtin to intracellular trafficking and endocytosis. Human Molecular Genetics 2002, 11:2815-2828.
232. Sommer D.B., Stacy M.A. What's in the pipeline for the treatment of Parkinson's disease?. Expert Review of Neurotherapeutics 2008, 8:1829-1839.
233. Song W., Chen J., Petrilli A., Liot G., Klinglmayr E., Zhou Y., Poquiz P., Tjong J., Pouladi M.A., Hayden M.R., Masliah E., Ellisman M., Rouiller I., Schwarzenbacher R., Bossy B., Perkins G., Bossy-Wetzel E. Mutant huntingtin binds the mitochondrial fission GTPase dynamin-related protein-1 and increases its enzymatic activity. Nature Medicine 2011, 17:377-382.
234. Sorensen S.A., Fenger K. Causes of death in patients with Huntington's disease and in unaffected first degree relatives. Journal of Medical Genetics 1992, 29:911-914.
235. Sperandio S., de Belle I., Bredesen D.E. An alternative, nonapoptotic form of programmed cell death. Proceedings of the National Academy of Sciences United States of America 2000, 97:14376-14381.
236. Stiles D.K., Zhang Z., Ge P., Nelson B., Grondin R., Ai Y., Hardy P., Nelson P.T., Guzaev A.P., Butt M.T., Charisse K., Kosovrasti V., Tchangov L., Meys M., Maier M., Nechev L., Manoharan M., Kaemmerer W.F., Gwost D., Stewart G.R., Gash D.M., Sah D.W.Y. Widespread suppression of huntingtin with convection-enhanced delivery of siRNA. Experimental Neurology 2011, 233:463-471.
237. Takahashi A., Alnemri E.S., Lazebnik Y.A., Fernandes-Alnemri T., Litwack G., Moir R.D., Goldman R.D., Poirier G.G., Kaufmann S.H., Earnshaw W.C. Cleavage of lamin A by Mch2 alpha but not CPP32: multiple interleukin 1 beta-converting enzyme-related proteases with distinct substrate recognition properties are active in apoptosis. Proceedings of the National Academy of Sciences United States of America 1996, 93:8395-8400.
238. Takano H., Gusella J.F. The predominantly HEAT-like motif structure of huntingtin and its association and coincident nuclear entry with dorsal, an NF-kB/Rel/dorsal family transcription factor. BMC Neuroscience 2002, 3:15.
239. Tang T.S., Slow E., Lupu V., Stavrovskaya I.G., Sugimori M., Llinas R., Kristal B.S., Hayden M.R., Bezprozvanny I. Disturbed Ca2+ signaling and apoptosis of medium spiny neurons in Huntington's disease. Proceedings of the National Academy of Sciences United States of America 2005, 102:2602-2607.
240. Tardiff D.F., Tucci M.L., Caldwell K.A., Caldwell G.A., Lindquist S. Different 8-Hydroxyquinolines Protect Models of TDP-43 Protein, alpha-Synuclein, and Polyglutamine Proteotoxicity through Distinct Mechanisms. Journal of Biological Chemistry 2012, 287:4107-4120.
241. Telenius H., Kremer H., Thellmann J., Andrew S., Almqvist E., Anvret M., Greenberg C., Greenberg J., Lucotte G., Squltierl F. Molecular analysis of juvenile Huntington disease: the major influence on (CAG) n repeat length is the sex of the affected parent. Human Molecular Genetics 1993, 2:1535-1540.
242. The Huntington's Disease Collaborative Research Group, 1993. A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes. Cell 72, 971-983.
243. Thornberry N.A., Bull H.G., Calaycay J.R., Chapman K.T., Howard A.D., Kostura M.J., Miller D.K., Molineaux S.M., Weidner J.R., Aunins J., et al. A novel heterodimeric cysteine protease is required for interleukin-1 beta processing in monocytes. Nature 1992, 356:768-774.
244. Thornberry N.A., Rano T.A., Peterson E.P., Rasper D.M., Timkey T., Garcia-Calvo M., Houtzager V.M., Nordstrom P.A., Roy S., Vaillancourt J.P., Chapman K.T., Nicholson D.W. A combinatorial approach defines specificities of members of the caspase family and granzyme B. Functional relationships established for key mediators of apoptosis. Journal of Biological Chemistry 1997, 272:17907-17911.
245. Thrall J.H. Prevalence and costs of chronic disease in a health care system structured for treatment of acute illness. Radiology 2005, 235:9-12.
246. Toulmond S., Tang K., Bureau Y., Ashdown H., Degen S., O'Donnell R., Tam J., Han Y., Colucci J., Giroux A., Zhu Y., Boucher M., Pikounis B., Xanthoudakis S., Roy S., Rigby M., Zamboni R., Robertson G.S., Ng G.Y., Nicholson D.W., Fluckiger J.P. Neuroprotective effects of M826, a reversible caspase-3 inhibitor, in the rat malonate model of Huntington's disease. British Journal of Pharmacology 2004, 141:689-697.
247. Tsai J., Lee J.T., Wang W., Zhang J., Cho H., Mamo S., Bremer R., Gillette S., Kong J., Haass N.K., Sproesser K., Li L., Smalley K.S., Fong D., Zhu Y.L., Marimuthu A., Nguyen H., Lam B., Liu J., Cheung I., Rice J., Suzuki Y., Luu C., Settachatgul C., Shellooe R., Cantwell J., Kim S.H., Schlessinger J., Zhang K.Y., West B.L., Powell B., Habets G., Zhang C., Ibrahim P.N., Hirth P., Artis D.R., Herlyn M., Bollag G. Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity. Proceedings of the National Academy of Sciences United States of America 2008, 105:3041-3046.
248. Vandenabeele P., Galluzzi L., Vanden Berghe T., Kroemer G. Molecular mechanisms of necroptosis: an ordered cellular explosion. Nature Reviews Molecular and Cellular Biology 2010, 11:700-714.
249. Vertex Pharmaceuticals, Inc., 2010. VX-765 (Epilepsy). Retrieved June 3, 2011 from http://www.vrtx.com/current-projects/drug-candidates/pipeline.html.
250. Viola H.M., Hool L.C. Cross-talk between L-type Ca2+ channels and mitochondria. Clinical and Experimental Pharmacology and Physiology 2010, 37:229-235.
251. Vonsattel J.P., DiFiglia M. Huntington disease. Journal of Neuropathology & Experimental Neurology 1998, 57:369-384.
252. Waelter S., Scherzinger E., Hasenbank R., Nordhoff E., Lurz R., Goehler H., Gauss C., Sathasivam K., Bates G.P., Lehrach H., Wanker E.E. The huntingtin interacting protein HIP1 is a clathrin and alpha-adaptin-binding protein involved in receptor-mediated endocytosis. Human Molecular Genetics 2001, 10:1807-1817.
253. Walker F.O. Huntington's disease. Lancet 2007, 369:218-228.
254. Waller J. A forgotten plague: making sense of dancing mania. Lancet 2009, 373:624-625.
255. Wang H., Lim P.J., Karbowski M., Monteiro M.J. Effects of overexpression of huntingtin proteins on mitochondrial integrity. Human Molecular Genetics 2009, 18:737-752.
256. Wang H., Chen X., Li Y., Tang T.S., Bezprozvanny I. Tetrabenazine is neuroprotective in Huntington's disease mice. Molecular Neurodegeneration 2010, 5:18.
257. Wang X., Zhu S., Drozda M., Zhang W., Stavrovskaya I.G., Cattaneo E., Ferrante R.J., Kristal B.S., Friedlander R.M. Minocycline inhibits caspase-independent and -dependent mitochondrial cell death pathways in models of Huntington's disease. Proceedings of the National Academy of Sciences United States of America 2003, 100:10483-10487.
258. Wang X., Wang H., Figueroa B.E., Zhang W.H., Huo C., Guan Y., Zhang Y., Bruey J.M., Reed J.C., Friedlander R.M. Dysregulation of receptor interacting protein-2 and caspase recruitment domain only protein mediates aberrant caspase-1 activation in Huntington's disease. Journal of Neuroscience 2005, 25:11645-11654.
259. Wanker E.E., Rovira C., Scherzinger E., Hasenbank R., Walter S., Tait D., Colicelli J., Lehrach H. HIP-I: a huntingtin interacting protein isolated by the yeast two-hybrid system. Human Molecular Genetics 1997, 6:487-495.
260. Warby S.C., Montpetit A., Hayden A.R., Carroll J.B., Butland S.L., Visscher H., Collins J.A., Semaka A., Hudson T.J., Hayden M.R. CAG expansion in the Huntington disease gene is associated with a specific and targetable predisposing haplogroup. American Journal of Human Genetics 2009, 84:351-366.
261. Warby S.C., Visscher H., Collins J.A., Doty C.N., Carter C., Butland S.L., Hayden A.R., Kanazawa I., Ross C.J., Hayden M.R. HTT haplotypes contribute to differences in Huntington disease prevalence between Europe and East Asia. European Journal of Human Genetics 2011, 19:561-566.
262. Wartha F., Henriques-Normark B. ETosis: a novel cell death pathway. Science Signaling 2008, 1:pe25.
263. Wellington C.L., Singaraja R., Ellerby L., Savill J., Roy S., Leavitt B., Cattaneo E., Hackam A., Sharp A., Thornberry N., Nicholson D.W., Bredesen D.E., Hayden M.R. Inhibiting caspase cleavage of huntingtin reduces toxicity and aggregate formation in neuronal and nonneuronal cells. Journal of Biological Chemistry 2000, 275:19831-19838.
264. Wilbur J.D., Chen C.Y., Manalo V., Hwang P.K., Fletterick R.J., Brodsky F.M. Actin binding by Hip1 (huntingtin-interacting protein 1) and Hip1R (Hip1-related protein) is regulated by clathrin light chain. Journal of Biological Chemistry 2008, 283:32870-32879.
265. Wild E.J., Tabrizi S.J. The differential diagnosis of chorea. Practical Neurology 2007, 7:360-373.
266. Wilkinson B., Gilbert H.F. Protein disulfide isomerase. Biochimica et Biophysica Acta 2004, 1699:35-44.
267. Wu H.Q., Lee S.C., Schwarcz R. Systemic administration of 4-chlorokynurenine prevents quinolinate neurotoxicity in the rat hippocampus. European Journal of Pharmacology 2000, 390:267-274.
268. Yorimitsu T., Klionsky D.J. Autophagy: molecular machinery for self-eating. Cell Death & Differentiation 2005, 12(Suppl 2):1542-1552.
269. Yu J., Zhu H., Ko D., Kindy M.S. Motoneuronotrophic factor analog GM6 reduces infarct volume and behavioral deficits following transient ischemia in the mouse. Brain Research 2008, 1238:143-153.
270. Zeitlin S., Liu J.P., Chapman D.L., Papaioannou V.E., Efstratiadis A. Increased apoptosis and early embryonic lethality in mice nullizygous for the Huntington's disease gene homologue. Nature Genetics 1995, 11:155-163.
271. Zhai W., Jeong H., Cui L., Krainc D., Tjian R. In vitro analysis of huntingtin-mediated transcriptional repression reveals multiple transcription factor targets. Cell 2005, 123:1241-1253.
272. Zhang Y., Leavitt B.R., van Raamsdonk J.M., Dragatsis I., Goldowitz D., MacDonald M.E., Hayden M.R., Friedlander R.M. Huntingtin inhibits caspase-3 activation. EMBO Journal 2006, 25:5896-5906.
273. Zheng H., Gal S., Weiner L.M., Bar-Am O., Warshawsky A., Fridkin M., Youdim M.B. Novel multifunctional neuroprotective iron chelator-monoamine oxidase inhibitor drugs for neurodegenerative diseases: in vitro studies on antioxidant activity, prevention of lipid peroxide formation and monoamine oxidase inhibition. Journal of Neurochemistry 2005, 95:68-78.
274. Zuccato C., Tartari M., Crotti A., Goffredo D., Valenza M., Conti L., Cataudella T., Leavitt B.R., Hayden M.R., Timmusk T., Rigamonti D., Cattaneo E. Huntingtin interacts with REST/NRSF to modulate the transcription of NRSE-controlled neuronal genes. Nature Genetics 2003, 35:76-83.
275. Zuccato C., Valenza M., Cattaneo E. Molecular mechanisms and potential therapeutical targets in Huntington's disease. Physiological Review 2010, 90:905-981.
276. Zuhlke C., Riess O., Bockel B., Lange H., Thies U. Mitotic stability and meiotic variability of the (CAG)n repeat in the Huntington disease gene. Human Molecular Genetics 1993, 2:2063-2067.